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pleted cells and 8 patients were treated at 104 cells/kg/dose and 8
patients received 105 cells/kg/dose. Patients receiving 105 cells/kg/
dose showed signiﬁcantly improved T-cell recovery at 3, 4 and 5
months post-SCT compared with those receiving 104 cells/kg/dose
(P  .05). Accelerated T-cell recovery occurred as a result of
expansion of the effector memory (CD45RACCR-7) population
(P  .05), indicating derivation from the infused allodepleted cells
and that protective T-cell responses are likely to be long-lived.
Using tetramer and ELISPOT assays, we have observed CMV and
EBV-speciﬁc responses in 4/6 evaluable patients at dose level 2 as
early as 2-4 months post-transplant, whereas such responses were
not observed until 6-12 months in dose level 1 patients. The
incidence of signiﬁcant acute (2/16) and chronic GVHD (2/13) was
low. At a median follow-up of 25 months, only 1 patient has died
from infection and 8 of 16 of these high-risk patients are disease-
free. These data demonstrate that allodepleted donor T-cells can
be safely be used to improve T-cell reconstitution after haploiden-
tical SCT and that total cell doses of 3  105/kg are sufﬁcient to
confer useful anti-viral immunity. This approach may broaden the
applicability of haploidentical SCT by reducing infection-associ-
ated mortality (Table 1).
Table 1. Comparison of CD3 ve T-Cell Recovery between Dose
















1 7 0 6 4 .215
2 7 2 6 20 .216
3* 7* 2* 6* 616* .016*
4* 6* 112* 6* 747* .017*
5* 6* 175* 6* 900* .04*
6 5 488 5 1421 .129
9 3 1047 2 1450 .787
*Signiﬁcant increases in T-cell numbers in dose level 2 compared
to dose level 1.
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PERIPHERAL CD4CD25 REGULATORY T CELLS (Treg) BLOCK ALLO-
REACTIVE HOST ANTI-DONOR T CELLS IN CANINE MIXED HEMATO-
POIETIC CHIMERAS
Lesnikova, M.1, Nikitine, A.1, Pogosov, L.1, Nash, R.A.1,2,
Georges, G.E.1,2 1Fred Hutchinson Cancer Research Center, Seattle,
WA; 2University of Washington, Seattle, WA.
CD4CD25 Treg cells may be important regulators for the
maintenance of immune tolerance after allogeneic hematopoietic
cell transplantation (HCT). In the canine model of nonmyeloab-
lative HCT, stable mixed hematopoietic chimerism persists follow-
ing 2 gray total body irradiation, dog leukocyte antigen (DLA)-
identical HCT and short-term postgrafting immunosuppression
with mycophenolate mofetil and cyclosporine. We hypothesized
that CD4CD25Treg are an important component of the cellular
mechanism maintaining stable mixed chimerism. We asked if de-
pletion of CD4CD25 Treg from peripheral blood mononuclear
cells (PBMC) from dogs with stable mixed chimerism could gen-
erate minor histocompatibility antigen (mHAg)-speciﬁc, host anti-
donor cytotoxic T lymphocytes (CTL). Responder PBMC from 4
mixed chimeric dogs were cultured in MLC with irradiated,
CD34 derived dendritic cells (DC) from the respective DLA-
identical HCT donor. On day 4 of MLC, CD4CD25 T cells
were depleted by either immunomagnetic selection (Miltenyi) us-
ing the CD25 monoclonal antibody (ACT-1) or the addition of
1011 M denileukin diftitox (DAB389IL-2, Ontak). DAB389IL-2 is
a fusion protein of the ADP-ribosyltransferase domain of diphthe-
ria toxin and IL-2. Depletion of CD4CD25bright was 60%-66%
with immunomagnetic selection and 70%-77% with DAB389IL-2.
A secondary MLC was established with CD4CD25 depleted
responder cells and DC from the respective DLA-identical HCT
donor. There was a 54%-95% increase in proliferation of cells
depleted of CD4CD25 T cells with immunomagnetic selection
and a 121%-133% increase in proliferation of DAB389IL-2 treated
cells compared with non-depleted responder cells. We evaluated
mHAg-speciﬁc CTL activity of the CD4CD25 depleted re-
sponder T cells by 51Cr release assay. There was 74%-82% speciﬁc
lysis of the respective HCT donor cells by the CD4CD25
depleted responder T cells, while the non-depleted control re-
sponder cells had 4%-6% speciﬁc lysis. PCR analysis with infor-
mative microsatellite markers conﬁrmed the alloreactive CTL
were of host origin. Depletion of CD4CD25 Treg from PBMC
of mixed chimeras permitted the emergence of host anti-donor
mHAg-speciﬁc CTL. The data suggest (1) mHAg-speciﬁc host
anti-donor T cells persist in stable mixed chimeric dogs, (2) pe-
ripheral CD4CD25 Treg prevent alloreactive immune re-
sponses, (3) mixed hematopoietic chimerism established without T
cell depletion relies on peripheral immune tolerance mechanisms.
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PR1 VACCINE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Qazilbash, M.H., Rios, R., Thall, P.F., Wang, X., Wieder, E., Lu, S.,
Kant, S., Giralt, S.A., Estey, E.H., Cortes, J., Champlin, R.E.,
Komanduri, K., Molldrem, J.J. University of Texas M.D. Anderson
Cancer Center, Houston, TX.
Background: PR1 peptide has been established as a humanmyeloid
leukemia-associated antigen. We studied PR1 peptide vaccine in a
phase I/II clinical trial in HLA-A2 patients with AML, MDS and
CML. There were concerns that prior hematopoietic stem cell trans-
plantation (HSCT)might inhibit an immune response to PR1 vaccine
due to impaired immune reconstitution. To address this question we
studied the outcome in 19 patients who received PR1 vaccine after a
HSCT. Methods: Nineteen patients (AML/MDS 13 and CML 6)
were vaccinated a median of 10 months after one of the following
HSCT: allogeneic related 12, allogeneic unrelated 3, autologous 3,
and syngeneic 1. At the time of vaccination, 7 patients were in CR, 5
had relapsed or refractory CML and 7 had relapsed or refractory
AML. Patients were off systemic immunosuppressive therapy for at
least 2 weeks, and without active acute or chronic GVHD. The
vaccine was given subcutaneously every 3 weeks for a total of 3
injections at one of three dose levels: 0.25, 0.5 and 1.0 mg. Immune
response to the vaccine (IRV) was deﬁned as a doubling of PR1-
speciﬁc cytotoxic T lymphocytes by PR1/HLA-A2 tetramer assay.
Results: After a median follow-up of 23 months, toxicity was limited
to grade I/II injection site reactions, with no exacerbations of acute or
chronic GVHD. PR1-vaccine induced immune responses were ob-
served in 9/18 (50%) evaluable patients. Of the 9 patients with PR1-
speciﬁc immune response, 6 remained in continuous complete remis-
sion (CCR), 2 patients with measurable disease achieved a complete
remission and 1 patient had hematologic improvement. Of the 9
patients without an immune response, 6 had no clinical response/
disease progression, 2 remained in CCR and 1 had hematologic
improvement. There was a signiﬁcant association between the devel-
opment of PR1-speciﬁc immune response and a clinical response (P
.03). Median progression-free survival (PFS) in IRV vs. IRV
patients was 23.4 months vs. 4.1 months, respectively (P  .36). On
univariate and multivariate Cox proportional hazards analysis, mini-
mal residual disease (P  .009) was associated with a lower risk of
progression. Conclusions: PR1 vaccine can produce a PR1-speciﬁc
immune response in patients after HSCT. This immune response is
associated with a better clinical response and a trend towards longer
progression-free survival.
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ACTIVATION OF LMP1- AND LMP2-SPECIFIC T-CELLS FOR THE IMMU-
NOTHERAPY OF EBV POSITIVE MALIGNANCIES WITH AN ADENOVIRAL
VECTOR ENCODING FULL LENGTH LMP1 AND LMP2
Ratnayake, M., Louis, C., Leen, A., Rooney, C.M., Brenner, M.K.,
Heslop, H.E., Gottschalk, S. Center for Cell and Gene Therapy at Baylor
College of Medicine, Houston, TX.
Background: LMP1 and LMP2 are potential targets for the
immunotherapy of EBV-positive malignancies such as nasopharyn-
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geal carcinoma (NPC) and Hodgkin’s disease (HD). We have
shown in the past that LMP1- and LMP2-speciﬁc T-cells can be
activated from EBV-seropositive individuals with adenoviral vec-
tors encoding either an inactive form of LMP1 (dLMP1) or LMP2.
The aim of this study was to construct and characterize an adeno-
viral vector containing dLMP1 and LMP2 (Ad_dLMP1-I-LMP2)
for the generation of LMP1- and LMP2-speciﬁc T cells. Meth-
ods: To evaluate the activity of Ad-dLMP1-I-LMP2 to reactivate
LMP1- and LMP2-speciﬁc CTL, we took advantage of the tro-
pism of Ad5F35 adenoviral vectors, which preferentially transduce
monocytes after incubation of peripheral blood mononuclear cells
(PBMC). Transduced monocytes expressed LMP1 and LMP2, and
reactivated LMP1- and LMP2-speciﬁc T cells, that could be ex-
panded further with autologous LCL transduced with Ad-dLMP1-
I-LMP2. The presence of LMP1- and LMP2-speciﬁc CTL was
determined by tetramer analysis, IFN- ELISPOT assays and
cytotoxicity assays. Results: Stimulation of PBMC with Ad-
dLMP1-I-LMP2 transduced monocytes from 10 HLA-A2, EBV-
seropositive donors resulted in an at least 30 to 100 fold expansion
of LMP1- or LMP2-speciﬁc T-cells as judged by the presence of
HLA-A2 restricted, tetramer positive T-cells. LMP2-speciﬁc re-
sponses were detected in all donors where as LMP1-speciﬁc re-
sponses were found in 7/10 donors. The presence of LMP1- and
LMP2-speciﬁc T-cells was conﬁrmed in a subset of donors with
IFN- ELISPOT assays. In addition, generated LMP1- and
LMP2-CTL killed autologous ﬁbroblasts expressing LMP1 and
LMP2, as well as LCL. Conclusion: The constructed adenoviral
vector, Ad-dLMP1-I-LMP2, is a promising candidate for the ex
vivo generation of LMP1- and LMP2-speciﬁc CTL and may also
be used as a vaccine for the in vivo boosting of adoptively trans-
ferred T cells. Targeting the subdominant LMP antigens ex-
pressed in NPC and HD may improve the efﬁcacy of adoptive
immunotherapy approaches.
LATE EFFECTS/QUALITY OF LIFE
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LONG-TERM OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION (HCT) FOR CML
Goldman, J.M., Sobocinski, K.A., Zhang, M.-J., Klein, J.P.,
Ketelsen, S.W., Giralt, S.A., Horowitz, M.M., Rizzo, J.D. Chronic
Leukemia Working Committee of the Center for International Blood and
Marrow Transplant Research, Milwaukee, WI.
We studied 6548 recipients of allogeneic HCTs performed be-
tween 1978 and 1997 to determine long-term rates of overall
survival, disease-free survival and relapse. As of December 2002,
2710 of the 6548 had survived for 	5 yr, 1926 for 	7 yr, 1044 for
	10 yr, 212 for 	15 yr and 7 for 	20 yr. 2234 patients were alive
and in continuing remission 5 or more years post-HCT. Of these,
the median age at HCT was 34 yrs, 60% had received TBI as part
of their conditioning; 67% had received cyclosporine and metho-
trexate for graft-versus-host disease (GVHD) prophylaxis. Among
patients alive and in remission 5 yrs after HCT, the cumulative
incidences of subsequent relapse at 15 yrs post-HCT were 17%,
15%, 12% and 7% for recipients of sibling transplants in ﬁrst
chronic phase (CP), recipients of sibling transplants not in ﬁrst CP,
recipients of alternative donor transplants in ﬁrst CP and recipients
of alternative donor transplants not in ﬁrst CP respectively. The
latest relapse occurred at 16 yr post HCT. Corresponding survival
rates at 15 years in the patients were 85%, 83%, 80% and 75%. 174
of the 2234 patients surviving in remission at 5 years post HCT
subsequently died; the causes of death were CML (2% of 5 year
survivors), GVHD (1%), second cancer (1%), infection (1.4%),
organ failure (1%) and other (1%). We conclude that remissions
after allogeneic HCT are generally durable. However, after a
high-risk period early post-HCT, there is a low but constant risk of
relapse. Rescue strategies in patients with late relapse may include
donor cell infusions or imatinib, though few data exist regarding
the efﬁcacy of these approaches in this patient group.
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DETECTION OF BCR-ABL EXPRESSION IN HUMAN CML MODEL USING
RADIOLABELED ANALOGUE OF ABL-PROTEIN KINASE INHIBITOR AND
POSITRON-EMISSION TOMOGRAPHY (PET)
Doubrovin, M.1, Beresten, T.1, Veach, D.1, Namavari, M.1,
Balatoni, J.2, Bornmann, W.2, Guelovani, J.2, Larson, S.1 1Memorial
Sloan-Kettering Cancer Center, New York, NY; 2M.D. Anderson Can-
cer Center, Houston, TX.
Introduction of imatinib marked a pivot point in history of
treatment of chronic myelogenic leukemia (CML). Speciﬁc inhi-
bition of bcr-abl kinase interrupts pathologic signal transduction
pathway, terminating tumor growth. To facilitate identiﬁcation of
the patients eligible for imatinib therapy we developed a non-
invasive in vivo imaging technique enabling detection of abl-kinase
expression by PET. A speciﬁc abl-protein kinase inhibitor (PKI)
DV was developed to be radiolabeled. K562—human CML cell
line (overexpressing bcr-abl) and A431—human GBM cell line (low
for abl) were chosen as models. Levels of abl expression were
conﬁrmed by Western blot. In vitro radiotracer accumulation
studies were done with [131I]DV. For in vitro studies subcutaneous
xenograft tumor models were created in contralateral shoulders of
nude rnu/rnu rats. Upon tumor size of 1 cm3, [124I]DL was injected
IV to the rats for 2 sets of scans: 40 Ci for microPET and 200 Ci
for clinical PET-Advance. Acquisition was performed in dynamic
10 min frames for 60 min on microPET and 90 min on PET-
Advance. After image reconstruction ROIs were analyzed for ra-
diotracer dynamics. MicroPET imaging showed accumulation of
[124I]DV in K562 tumor with low background signal in the rest of
the animal. Maximal accumulation in early frames appeared to be
in projection of liver. Imaging on clinical PET-Advance scanner
demonstrated speciﬁc accumulation of [124I]DV radiotracer in hu-
man CML K562 tumor model over 90 min of imaging session. No
accumulation in abl-negative A431 was detected. There was con-
current monophasic clearance of the radiotracer form the circula-
tion. Initial high concentration of the radiotracer in the liver was
gradually clearing out with concomitant increase of bowel signal
demonstrating hepato-biliary clearance. Non-invasive assessment
of bcr-abl expression is feasible by PET-visualization using
[124I]DV, radiolabeled abl-PKI. Detection of bcr-abl expression in
vivo will not only assist identifying treatment target for imatinib
therapy in patients, it might assist monitoring the course of CML
therapy with imatinib. This method can also be used as a screening
option for selection of patients with abl-overexpression in other
types of tumors.
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GM-CSF SECRETING LEUKEMIA CELL VACCINATIONS AFTER ALLOGE-
NEIC NON-MYELOABLATIVE PERIPHERAL BLOOD STEM CELL TRANS-
PLANTATION IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYN-
DROME OR REFRACTORY ACUTE MYELOID LEUKEMIA
Ho, V.T., Dranoff, G., Pasek, M., MacDonell, R., Cutler, C., Lee, S.J.,
Alyea, E.P., Antin, J.H., Soiffer, R.J. Dana-Farber Cancer Institute,
Boston, MA.
Disease relapse is a frequent cause of treatment failure in patients
undergoing non-myeloablative allogeneic stem cell transplantation
(NST) for advanced myelodysplastic syndrome (MDS) and acute
myeloid leukemia (AML). GVAX, a cancer vaccine composed of
leukemia cells modiﬁed by adenoviral vector mediated gene trans-
fer to secrete GM-CSF, has demonstrated activity in MDS and
AML. We initiated a trial investigating the feasibility and safety of
administering GVAX after allogeneic NST. Patients with MDS-
RAEB or AML not in remission with a donor matched at HLA-
A,B, and DRB1 were eligible. Leukemia blasts were collected for
GVAX generation prior to conditioning. The preparative regimen
consisted of ﬂudarabine 30 mg/m2/d IV days 6 to 3, and
Busulfex 0.8 mg/kg IV q12h  8 doses from days 6 to 3. All
patients received G-CSF mobilized PBSC. GVHD prophylaxis
included tacrolimus starting day3, and methotrexate 5 mg/m2 IV
days 1, 3, 6, 11. GM-CSF (Leukine) 250 mg/m2 SC QD was given
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